SCHEMBL3203157

SCHEMBL3203157

CCOC(=O)C1CN(C(=O)OC(C)(C)C)c2cccc(Br)c2O1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.40
CTDSP1 Q9GZU7 1/20 0.40
UCHL1 P09936 1/20 0.40
POLB P06746 1/20 0.39
KMT2A Q03164 6/20 0.39
MEN1 O00255 4/20 0.39
ALDH1A1 P00352 6/20 0.37
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
RECQL P46063 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
KDM1A O60341 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
MAPT P10636 1/20 0.34
NR1H2 P55055 1/20 0.34
NR1H3 Q13133 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3356484 0.84 POLB (0.44) TDP1POLBKMT2AMEN1ALDH1A1
SCHEMBL925973 0.84 POLB (0.49) POLBKMT2AMEN1ALDH1A1
SCHEMBL3196270 0.81 POLB (0.43) TDP1CTDSP1POLBKMT2AMEN1
SCHEMBL30479646 0.81 UCHL1 (0.44) UCHL1KDM1AHDAC1HDAC6NR1H2
SCHEMBL3205346 0.81 UCHL1 (0.44) UCHL1KDM1AHDAC1HDAC6NR1H2
SCHEMBL25980404 0.80 UCHL1 (0.43) UCHL1KMT2AMEN1KDM1AHDAC1
SCHEMBL30479638 0.78 UCHL1 (0.42) UCHL1KMT2AMEN1KDM1AHDAC1
SCHEMBL25980444 0.78 UCHL1 (0.42) UCHL1KMT2AMEN1KDM1AHDAC1
SCHEMBL3351602 0.78 POLB (0.44) POLBKMT2AMEN1ALDH1A1CYP3A4
SCHEMBL30479612 0.78 UCHL1 (0.41) UCHL1KDM1AHDAC1HDAC6NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4472734-A1 HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS C4X Discovery Limited (GB) 2024-12-11 EP disclosed
WO-2023148501-A1 HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS C4X DISCOVERY LIMITED (GB) 2023-08-10 WO disclosed
WO-2023148501-A1 HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS C4X DISCOVERY LIMITED (GB) 2023-08-10 WO disclosed
US-20100035871-A1 BENZOXAZINE DERIVATIVES AND USES THEREOF WYETH 2010-02-11 US disclosed
US-20100035871-A1 BENZOXAZINE DERIVATIVES AND USES THEREOF WYETH 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035871-A1 BENZOXAZINE DERIVATIVES AND USES THEREOF HTR2C, HTR5A, NPY1R TDP1 2282/4885CTDSP1 3846/4885UCHL1 2156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.